Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
50
MDGL Quote, Financials, Valuation and Earnings
Last price:
$310.66
Seasonality move
:
15.43%
Day range:
$293.00 - $312.52
52-week range:
$168.25 - $368.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.66x
Volume:
696.5K
Avg. volume:
390.4K
1-year change:
39.66%
Market cap:
$6.7B
Revenue:
--
EPS (TTM):
-$25.12
Analysts' Opinion
-
Consensus RatingMadrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Madrigal Pharmaceuticals has an estimated upside of 20.83% from its current price of $308.71.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $308.71.
Fair Value
-
According to the consensus of 0 analysts, Madrigal Pharmaceuticals has 20.83% upside to fair value with a price target of -- per share.
MDGL vs. S&P 500
-
Over the past 5 trading days, Madrigal Pharmaceuticals has overperformed the S&P 500 by 3.44% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Madrigal Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Madrigal Pharmaceuticals revenues have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Madrigal Pharmaceuticals reported revenues of $62.2M.
Earnings Growth
-
Madrigal Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Madrigal Pharmaceuticals reported earnings per share of -$4.92.
Enterprise value:
5.9B
EV / Invested capital:
6.54x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.40x
EV / Free cash flow:
-13.35x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-62.74%
Net Income Margin (TTM):
--
Return On Equity:
-89.04%
Return On Invested Capital:
-74.25%
Operating Margin:
-187.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $62.2M | |
| Gross Profit | -- | -- | -- | -- | $60M | |
| Operating Income | -$272.9M | -$348.6M | -$548.1M | -$98.5M | -$116.3M | |
| EBITDA | -$271.3M | -$336.4M | -$502.7M | -$95.1M | -$103M | |
| Diluted EPS | -$16.03 | -$19.24 | -$25.12 | -$5.34 | -$4.92 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $337.6M | $303M | $157.1M | $235.5M | $1.1B | |
| Total Assets | $339.6M | $304.7M | $158.6M | $238M | $1.1B | |
| Current Liabilities | $49.4M | $69.3M | $98.9M | $99.7M | $177.8M | |
| Total Liabilities | $49.9M | $69.8M | $148M | $215.7M | $296.1M | |
| Total Equity | $289.7M | $234.9M | $10.7M | $22.2M | $777.2M | |
| Total Debt | -- | -- | $49M | $114.7M | $117.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$214.4M | -$302.8M | -$431M | -$84.9M | -$67M | |
| Cash From Investing | $155.9M | -$74M | -$588.6M | $50.2M | -$202.4M | |
| Cash From Financing | $68.6M | $379.5M | $1.2B | $19.6M | $7.5M | |
| Free Cash Flow | -$214.7M | -$303.3M | -$438.3M | -$85.3M | -$67.8M | |
MDGL
Sector
Market Cap
$6.7B
$43.9M
Price % of 52-Week High
83.82%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
-13.76%
-0.74%
1-Year Price Total Return
39.66%
-29.11%
Beta (5-Year)
-0.418
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$303.23
200-day SMA
Buy
Level
$257.20
Bollinger Bands (100)
Buy
Level
218.15 - 309.67
Chaikin Money Flow
Sell
Level
-36.6M
20-day SMA
Sell
Level
$316.92
Relative Strength Index (RSI14)
Buy
Level
51.24
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-50.7103
50-day SMA
Buy
Level
$288.91
MACD (12, 26)
Buy
Level
0.26
25-day Aroon Oscillator
Buy
Level
24
On Balance Volume
Sell
Level
-59.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Stock Forecast FAQ
In the current month, MDGL has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDGL average analyst price target in the past 3 months is --.
-
Where Will Madrigal Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Madrigal Pharmaceuticals share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Madrigal Pharmaceuticals?
Analysts are divided on their view about Madrigal Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Madrigal Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.
-
What Is Madrigal Pharmaceuticals's Price Target?
The price target for Madrigal Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDGL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Madrigal Pharmaceuticals is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDGL?
You can purchase shares of Madrigal Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Madrigal Pharmaceuticals shares.
-
What Is The Madrigal Pharmaceuticals Share Price Today?
Madrigal Pharmaceuticals was last trading at $310.66 per share. This represents the most recent stock quote for Madrigal Pharmaceuticals. Yesterday, Madrigal Pharmaceuticals closed at $308.71 per share.
-
How To Buy Madrigal Pharmaceuticals Stock Online?
In order to purchase Madrigal Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
